Tag: NICE
-
Announcement of UK IDAP Pilot for medical devices – What does it mean for reimbursement?
The Innovative Devices Access Pathway (IDAP) Pilot is a first step to providing a faster and supported route to regulatory approval, access and adoption of innovative devices. But what precisely does this mean ultimately for access and reimbursement?
-
Microbiome-targeting medicines: Commercial launch is moving centre stage
While Europe still lags behind in terms of microbiome medicines approvals, in the UK, we have seen the first Health Technology Assessment (HTA) for microbiota medicines. Let’s have a closer look…
-
March 2023 Monthly Reading List
….What we were reading in March….
-
January 2023 Market Access Reading List
Recent news and articles to think about value and evidence development. This month, the news recap comes as short reading lists.
-
November Market Access news recap
November market access news recap For the November recap a few news snippets from the pharma and digital health world: RWE collection in Germany, the Hemgenix gene therapy, early value assessment in England as well as the dynamic French digital health policy landscape. … as usual, three minutes of your time …
-
August & September 2022 Market Access news recap
After the summer break, let’s quickly catch-up with selected August and September news from the access and reimbursement sphere….